Pre-specified exploratory analysis of SURPASS-CVOT (type 2 diabetes with atherosclerotic disease): tirzepatide cut major kidney events vs dulaglutide (6.0% vs 7.6%; HR 0.77) over median 4.0 years. Nausea, vomiting and diarrhoea were more common with tirzepatide.
Secondary analysisn = 13,165
Zoungas et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial